Search
for

    GlossaryWoodhouse-Sakati syndrome

    rare genetic disorder causing hair loss, diabetes, and other symptoms

    Woodhouse-Sakati syndrome is a rare genetic disorder characterized by a combination of symptoms including hair loss (alopecia), diabetes, hearing loss, intellectual disability, and hypogonadism (underdeveloped sex organs). It is caused by mutations in the DCAF17 gene and is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.

    Related Terms

    Learn

    5 / 801 results

    Research

    5 / 104 results

    Community Join

    5 / 1000+ results

      community 5 Months Finasteride + Minoxidil

      in Progress Pictures  676 upvotes 3 years ago
      This user has achieved impressive results after 5 months of using Finasteride and Minoxidil, which appear to have stopped hair loss and stimulated new growth. They have also incorporated derma pen treatments and supplements such as Zinc picolinate and DMAE into their regimen.

      community AA and Hirsutism but T levels are normal

      in Female  7 upvotes 5 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community The Worst Hair Loss Condition You (MAY) have: LPP

      in Research/Science  51 upvotes 1 year ago
      Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.